Immunohistochemical Profile of Synovial Sarcoma with Emphasis on the Epithelial-type Differentiation

Molecular mechanisms underlying human synovial sarcoma development

“…Several studies have demonstrated that immunohistochemistry may be of help in the diagnosis of MSS since these tumors are generally positive for epithelial markers (e.g., cytokeratins and EMA) that are mostly absent in other soft-tissue sarcomas such as fibrosarcomas (Miettinen, 1991;Lopes et al, 1994). Furthermore, MSS cases are usually negative for muscle-associated markers (e.g., desmin and smooth-muscle actin), allowing a distinction from leiomyosarcoma, and infrequently express S100 protein, which is present in the majority of MPNST cases (Miettinen, 1991;Lopes et al, 1994). PDSS may also be difficult to discern from other soft-tissue tumors, especially peripheral neuroectodermal and high-grade MPNST tumors.…”

Usefulness of Cytokeratin Subsets for Distinguishing Monophasic Synovial Sarcoma From Malignant Peripheral Nerve Sheath Tumor

“…According to the literature, approximately 90% of all synovial sarcomas are CK-positive. [4][5][6][7][8][9] EMA is expressed in almost all synovial sarcomas, with a frequency that is similar to or even higher than that of CK. 16 It has become increasingly recognized that a significant proportion of synovial sarcomas express S-100 protein.…”

Synovial Sarcoma of the Buccal Mucosa: A Rare Case Report

“…Regardless of the subtype, the conventional clues and immunohistochemical evidence of the epithelial element are characteristic of synovial sarcoma, and have led to the consensus that this tumor should be regarded as a carcinosarcoma of soft tissue origin [16]. In addition to the three subtypes, Enzinger and Weiss have described a “poorly differentiated” type of SS which shows more aggressive behavior [17].…”